Comerica Bank’s Heron Therapeutics HRTX Stock Holding History

Comerica Bank’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$6.44K	Sell	4,951 -68	-1%	-$84	﹤0.01%	3351
2025 Q3	$6.32K	Hold	5,019	–	–	﹤0.01%	3360
2025 Q2	$10.4K	Hold	5,019	–	–	﹤0.01%	3199
2025 Q1	$11K	Hold	5,019	–	–	﹤0.01%	3150
2024 Q4	$7.68K	Hold	5,019	–	–	﹤0.01%	3233
2024 Q3	$9.99K	Buy	5,019 +4,740	+1,699%	+$11.3K	﹤0.01%	3184
2024 Q2	$977	Hold	279	–	–	﹤0.01%	3585
2024 Q1	$772	Sell	279 -74	-21%	-$186	﹤0.01%	3644
2023 Q4	$600	Sell	353 -142	-29%	-$156	﹤0.01%	3660
2023 Q3	$510	Buy	+495	New	+$704	﹤0.01%	3708

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Comerica Bank's HRTX Position: Q4 2025 in Review

Comerica Bank reduced its Heron Therapeutics (HRTX) stake by 1.4% in Q4 2025, selling an estimated $84 and leaving 4,951 shares worth $6.44K. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

Comerica Bank first reported a position in HRTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $11K in Q1 2025. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

Comerica Bank held 4,951 shares of Heron Therapeutics worth $6.44K as of Q4 2025.
Comerica Bank sold 68 Heron Therapeutics shares in Q4 2025, an estimated $84.
Heron Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3351 holding.
Comerica Bank first reported a position in Heron Therapeutics in Q3 2023 and has held it in 10 quarters since.
Comerica Bank's Heron Therapeutics position peaked at $11K in Q1 2025.
170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.